Dyne Therapeutics Inc
NASDAQ:DYN

  • LAST PRICE
    28.1600
  • TODAY'S CHANGE (%)
    1.5400 (5.7851%)
  • Bid / Lots
    27.7200/ 1
  • Ask / Lots
    28.1600/ 1
  • Open / Previous Close
    26.9100 / 26.6200
  • Day Range
    26.4700
    28.4300
  • 52 Week Range
    6.4000
    30.2687
  • Volume
    650,219

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
DYN
Dyne Therapeutics Inc
2.3B
-7.1x
---
VERA
Vera Therapeutics Inc
2.2B
-20.0x
---
GERN
Geron Corp
2.2B
-10.6x
---
RNA
Avidity Biosciences Inc
2.5B
-9.8x
---
RCKT
Rocket Pharmaceuticals Inc
2.1B
-8.2x
---
JANX
Janux Therapeutics Inc
2.6B
-39.1x
---
As of 2024-05-14

Company Information

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Contact Information

Headquarters
1560 Trapelo RoadWALTHAM, MA, United States 02451
Phone
781-786-8230
Fax
781-786-8866

Executives

Independent Chairman of the Board
Jason Rhodes
President, Chief Executive Officer, Director
John Cox
Chief Operating Officer
Susanna High
Senior Vice President, Head of Finance and Administration
Richard Scalzo
Chief Scientific Officer
Oxana Beskrovnaya

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.3B
Revenue (TTM)
$0.00
Shares Outstanding
87.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.00
EPS
$-3.97
Book Value
$1.49
P/E Ratio
-7.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.